ClinicalTrials.gg

Program

EVER001

A development code.

Its studies are mostly in Glomerulonephritis, Membranous · Nephrosis, Lipoid, led by Everest Medicines (China).

Furthest: phase 2, since May 5, 20262 company-led studies, 1 open or runningNext primary completion: Dec 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Everest Medicines (China)21 open or runningphase 2since May 5, 2026Mar 9, 2023Dec 31, 2028phase 2 · NCT07614477

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 9, 2023First study: phase 1 study in Primary Membranous NephropathyFirst studyNCT05800873 · 31 enrolled · China
  2. May 5, 2026Phase 2 study in Nephrosis, LipoidPhase 2 reachedNCT07614477 · 45 planned · China

Ahead

  1. Dec 31, 2028Primary completion: phase 2 study in Nephrosis, LipoidNCT07614477

TargetBeta

BTK →read by rule
“EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases.”study text, by rule · the study

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07614477Nephrosis, Lipoid · China2RecruitingDec 31, 202845
NCT05800873Primary Membranous Nephropathy · China1CompletedJul 27, 202631

How it is read

Names in the registry

  • “EVER001”, 3 entries

Codes read as this program: EVER001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.